"2020 has been one of the most challenging years for the world with an
unprecedented pandemic impact on the global economy. We continue to
face headwinds across operational, regulatory and commercial functions
which have been deterrents to our planned market expansion. However,
we expect normalization by next fiscal," said Kiran Mazumdar-Shaw,
executive chairperson, Biocon.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-reports-17-drop-in-net-profit-christiane-hamacher-steps-down-as-md-of-biocon-biologics/articleshow/80398306.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment